Contents:

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1 Study Reliability and Reporting Limitations 1 Disclaimers 2 Data Interpretation & Reporting Level 3 Quantitative Techniques & Analytics 3 Product Definitions and Scope of Study 3 Bare Metal Stents 3 Drug Eluting Stents 4 2. GLOBAL MARKET OVERVIEW 5 Growth Revives as Drug Eluting Stents Bounce Back 5 What's Next on Cards in Coronary Stent Market? 5 Market Snapshots 6 Current and Future Analysis 7 Drug Eluting Stents Steal the Show 7 Star Player J&J to Quit DES Business in an Expensive Market Withdrawal 8 3. MARKET TRENDS AND ISSUES 9 Drug Eluting Stent System - Safety Concerns 9 Declining Prices - A Major Concern 9 Restenosis - the Real Growth Driver 9 Small Vessels - A Major Cause of Restenosis 10 Aging Population Propels Coronary Stent Market 10 Next Generation Stents - A Boon for Treating Coronary Diseases 10 Direct Stenting Systems Spur Growth 11 Drug Choice Impacts Market Entry 11 Threats to Coronary Stents - Alternative Therapies/Devices 11 Cell Transplantation - A Major Threat to Coronary Stents 11 Coronary Stents Market Challenged by Drug Therapy 12 4. COMPETITIVE ANALYSIS 13 Coronary Stents - Leading Players 13 Table 1: Leading Players in the Global Coronary Stents Market (2010 & 2012) - Percentage Breakdown of Market Share by Company - Boston Scientific, Abbott (Guidant), Johnson & Johnson, Medtronic, and Others (includes corresponding Graph/Chart) 13 Bare Metal Stents - Leading Players 14 Table 2: Leading Players in the Global Bare Metal Stents Market (2010) - Percentage Breakdown of Share for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) 14 Drug-Eluting Stents - Leading Players 14 Table 3: Global Drug Eluting Stents Market (2010): Percentage Breakdown of Share by Company - Boston Scientific, Abbott Labs, Johnson and Johnson, Medtronic, Others (includes corresponding Graph/Chart) 14 Major DES Types in the Market and Leading Manufacturers 14 Comparative Analysis of the Leading Players 15 5. CORONARY DISEASE - A PERSPECTIVE 16 Factors Responsible for Coronary Diseases 16 Controllable Risk Factors 16 High Blood Cholesterol 16 Sedentary Life Style and Habits 16 Smoking Habits 17 High Blood Pressure 17 Uncontrollable Risk Factors 17 Age 17 Heredity 17 Gender 17 Causative Risk Factors 17 Stress and Anger 18 Obesity 18 Diabetes 18 Symptoms of Coronary Artery Disease 18 Diagnosis 18 Treatment 19 Drug Supported Treatments 19 Invasive Treatments 19 Bypass Surgery 19 Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty) 19 Natural Therapy 20 Coronary Angioplasty Suitable for Acute Myocardial Infarction 20 Advancements in Coronary Disease Treatment Modalities 20 University of Virginia's Microbe Solution for Post Surgical Complications 20 Radiation for Re-clogged Arteries Show Promise 21 Radioactive Coronary Stents Promise Bright Future 21 6. CORONARY STENTS - PRODUCT OVERVIEW 22 Introduction 22 Evolution of Coronary Stents 22 Applications of Coronary Stents 22 Stent Deployment 23 Key Stent Delivery Platforms by Select Company 24 Coronary Stent Designs 24 Key Factors Determining Coronary Stent Performance 24 Delivery Convenience 24 Efficient Scaffolding 24 Radiopacity (Visibility) 25 Optimum Flexibility 25 Shape Conformability 25 Material for Coronary Stent 25 Risk Associated with Stenting 25 Improper Stent Implantation Likely Cause for In-Stent Restenosis 26 Precautions 27 Direct Coronary Stenting - Creating an Enliven 27 Limitations 27 Regulatory Approvals Wooing Stent Market 28 A Peek into Regulatory Approvals for Coronary Stents 28 7. PRODUCT SEGMENTS 30 Bare Metal Stents 30 Major Bare Metal Stents by Company 30 Drug-Eluting Stents 30 DE Stents Overshadow Intravascular Brachytherapy Interventions 31 Major Drug-Eluting Stents by Company 31 Drugs for Coating DESs 31 Cytotoxic or Cytostatic Drug - the Debate Continues 32 Dosing and Deliverability Crucial for DES 32 Polymer Coatings for Effective Dosing and Deliverability 32 Drugs Used for DES by Major Competitors in the Stent Market 32 Leading Coronary Stent Brands 33 Cypher 33 Structure and Delivery Mechanism 33 Taxus 34 Structure and Delivery Mechanism 34 8. RESEARCH AND DEVELOPMENT 35 Extensive R&D Underway in Global Drug-Eluting Stents Market 35 At the Labs 35 Other Products Under Trials - A Recent Past Perspective 35 OMT Developing R-stent 35 Reva Developing Stainless Steel Bare-Metal Stent 35 D&P Corp Developing Bovine Pericardium- Covered Stent 36 Advanced Bio Synthesizing Porous Drug-Eluting Stents 36 Lombard Medical Developing PEP Coatings 36 Shiga Develops Biodegradable Drug-Eluting Stent 36 9. PRODUCT INNOVATIONS/INTRODUCTIONS 37 Boston Scientific Launches ION™ Platinum Chromium Stent System 37 Terumo Introduces Nobori Drug-Eluting Coronary Stent 37 Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™ Stent Systems 37 Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent System 38 Boston Scientific Launches Taxus Element Stent System in European Union 38 Cordis Introduces PRESILLION™ PLUS Stent System in Europe 38 Medtronic Launches Resolute Integrity Stent System 38 InspireMD Unveils MGuard Prime 39 Boston Scientific Introduces Taxus Eluting Stent System 39 Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting Stent System in Japan 39 Alvimedica Launches Coracto Drug-Eluting Stent in Europe 39 Abbott Labs to Launch XIENCE V in China 40 Medtronic Launches Driver Sprint RX Coronary STENT System 40 Existent Introduces Premier Coronary Stent System 40 Medtronic to Unveil Balloon Catheter Systems and Coronary Stents 40 NanoInterventions Launches Mouse Stent Model 40 InspireMD - MGuard™ Coronary Stent Launched in Italy 41 CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin Polyzene®-F 41 Angiotech Launches Cook Medical's Drug Eluting Zilver® PTX™ Stent in New Zealand 41 10. RECENT INDUSTRY ACTIVITY 42 Boston Scientific Receives FDA Approval for Novel Paclitaxel- Eluting Coronary Stent 42 Boston Scientific Receives Approval for Distribution of PROMUS® Everolimus-Eluting Stent 42 Cordis Discontinues Production of NEVO™ Sirolimus- Eluting Coronary Stents 42 Boston Scientific Receives FDA Approval for ION Stent 43 Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid Stent System Application 43 Boston Scientific Receives CE Mark Approval for OMEGA™ Platinum Chromium Stent System 43 Stentys Launches Stents across Additional Countries in Europe 44 Opto Circuits Acquires N.S. Remedies 44 Biosensors International Group Takes Over Assets of Devax 44 Cordis Signs Distribution Agreement with Ostial Solutions 44 Medtronic Obtains FDA Approval for Integrity Coronary Stent System 44 Boston Scientific Receives Approval from Japanese MHLW for PROMUS® Coronary Stent 45 InspireMD Selects Kirloskar Technologies for Distributing Coronary Stent Systems 45 Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary Stent System 45 Boston Scientific Receives TGS Approval from Australia 46 Svelte Medical Systems Commences Clinical Trial of SOAW Delivery System 46 Abbott Receives Japans MHLW Approval for Xience V 46 Opto Circuits Receives Mark Approval from Communite European 46 Abbott Receives Health Canada Approval for XIENCE V® Stent System 46 Medtronic Secures Japans MHLW Approval for Endeavor® Drug Eluting Stent 47 Boston Scientific Takes Over Labcoat 47 Micell and Maxcor Sign Strategic Agreement 47 Cordis Receives FDA Approval for Variant of Cypher Sirolimus- Eluting Coronary Stent 47 Boston Scientific Obtains CE Mark Approval for Promus Element Everolimus-Eluting Coronary Stent System 47 Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE Mark for Treatment in Diabetic Patients 48 Atrium Medical Obtains CE Mark for Cinatra™ 48 Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting Stent for Use in Treatment of ACS 48 CorNova® Obtains CE mark approval for Valecor Platinum Coronary Stent System 48 Cook Medical Receives CE Mark Approval and Launches Zilver® PTX® Drug-Eluting Peripheral Stent 49 Disa Receives CE Approval for Coronary Stent 49 Datascope Acquires Peripheral Stent Business of Sorin Group 49 Boston Scientific Receives FDA approval for TAXUS® Liberte® Drug-Eluting STENT 49 Abbott Labs Receives FDA Approval for Xience V 49 Bard to Purchase Assets of LifeStent Product Portfolio 50 Medtronic Receives the US FDA Approval to Use Endeavor® Stent 50 Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In Canada 50 Boston Scientific to Market TAXUS® Liberte® Stent System in Canada 50 Abbott Applies for Approval of XIENCE™ V in Japan 51 Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent System 51 Iberhospitex Receives Spanish Approval to Sell Palau Pharma's “Active” Coronary Stent 51 Clearstream's Intrepide Drug Eluting Stent of Clearstream Receives CE mark approval 51 Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European Entry 52 Tryton Medical's Side-Branch Stent Achieves CE Mark Approval 52 CV Therapeutics Offers its Stent Coating Technology to Medlogics Device Corporation 52 Abbott's 2.25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of Approval 52 Biosensors Receives CE Mark Approval for BioMatrix® Stent System 53 Nfocus Neuromedical's CardioVasc™ Stent-Graft and Delivery System Receives CE Mark Approval 53 11. FOCUS ON SELECT GLOBAL PLAYERS 54 Angiotech Pharmaceuticals (Canada) 54 Abbott Vascular (USA) 54 Biosensors International (USA) 54 Boston Scientific Corp. (USA) 55 Cordis Corporation (JNJ) - (USA) 55 Medtronic, Inc. (USA) 56 Medtronic Cardiovascular, Inc. (USA) 56 OrbusNeich (Hong Kong) 56 Terumo Europe N.V. (Belgium) 56 12. GLOBAL MARKET PERSPECTIVE 57 Table 4: World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 57 Table 5: World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 58 Table 6: World Historic Review for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 59 Table 7: World Historic Review for Coronary Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart) 60 Table 8: World 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 61 Table 9: World 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 62 Table 10: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 63 Table 11: World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment-Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 64 Table 12: World Historic Review for Coronary Stents by Product Segment-Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 65 Table 13: World Historic Review for Coronary Stents by Product Segment-Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart) 66 Table 14: World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 67 Table 15: World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 68 Table 16: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 69 Table 17: World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 70 Table 18: World Historic Review for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sale sin US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart) 71 Table 19: World Historic Review for Bare Metal Stents By Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart) 72 Table 20: World 15-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 73 Table 21: World 15-Year Perspective for Bare Metal Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 74 Table 22: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 75 Table 23: World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia - Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2009 through 2017 (includes corresponding Graph/Chart) 76 Table 24: World Historic Review for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 77 Table 25: World Historic Review for Drug Eluting Stents by Geographic Region - US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart) 78 Table 26: World 15-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 79 Table 27: World 15-Year Perspective for Drug Eluting Stents by Geographic Region - Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 80 13. THE UNITED STATES 81 A.Market Analysis 81 Largest Market Worldwide 81 Coronary Artery Disease - A US Perspective 81 Baby Boomers Boost Coronary Stent Market 81 Revival in the DES Market 81 Reimbursement System 82 National Average Medicare Payment For DRGS 82 Competitive Scenario 82 Leading Players 82 Coronary Stents - Boston Scientific and JNJ Battle for Dominance 82 Table 28: Leading Players in the US Coronary Stents Market (2010) - Percentage Breakdown of Share for Boston Scientific, Abbott and Johnson & Johnson (includes corresponding Graph/Chart) 83 Drug Eluting Stents - Competition in the Brewing 83 Table 29: Leading Players in the US Drug-Eluting Stents Market (2010) - Percentage Breakdown of share for Boston Scientific, Abbott Labs, J&J-Cordis and Medtronic (includes corresponding Graph/Chart) 83 Regulatory Environment 84 B.Market Analytics 84 Table 30: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 84 Table 31: US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 85 Table 32: US Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 86 Table 33: US Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 87 Table 34: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 88 Table 35: US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 89 14. JAPAN 90 A.Market Analysis 90 Prospects Weighed down by Regulatory Entanglements 90 Japanese Coronary Stents Command Higher Prices 90 Table 36: Coronary Stent Pricing (2008): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart) 90 Competitive Landscape 91 Table 37: Leading Players in the Japanese Coronary Stent Market ( 2010) - Percentage Breakdown of Share for Johnson & Johnson, Medtronic, Boston Scientific, and Others (includes corresponding Graph/Chart) 91 Table 38: Leading Players in the Japanese Bare Metal Stent Market (2010) - Percentage Breakdown by of Share for Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart) 92 Table 39: Leading Players in Japanese Drug-Eluting Stent Market (2010) - Percentage Breakdown of Share for Johnson & Johnson and Boston Scientific (includes corresponding Graph/Chart) 92 B.Market Analytics 93 Table 40: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 93 Table 41: Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 94 Table 42: Japanese Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 95 Table 43: Japanese Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 96 Table 44: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 97 Table 45: Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 98 15. EUROPE 99 A.Market Analysis 99 Cardiovascular Disease in Europe - A Perspective 99 Growth Bar Too Low 99 Two-Speed Europe 99 Stent Market's Merger Mania 100 Dampeners to Rapid Adoption of DES in Europe 100 Competitive Scenario 101 Table 46: Leading Players in the European Drug- Eluting Stent Market (2010) - Percentage Breakdown of Share for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart) 101 B.Market Analytics 102 Table 47: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 102 Table 48: European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years2009 through 2017 (includes corresponding Graph/Chart) 103 Table 49: European Historic Review for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 104 Table 50: European Historic Review for Coronary Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 105 Table 51: European 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 106 Table 52: European 15-Year Perspective for Coronary Stents by Geographic Region - Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2075 (includes corresponding Graph/Chart) 107 Table 53: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 108 Table 54: European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 109 Table 55: European Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 110 Table 56: European Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 111 Table 57: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 112 Table 58: European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 113 15a. FRANCE 114 Market Analysis 114 Table 59: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 114 Table 60: French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 115 Table 61: French Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 116 Table 62: French Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 117 Table 63: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 118 Table 64: French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 119 15b. GERMANY 120 Market Analysis 120 Table 65: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 120 Table 66: German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 121 Table 67: German Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 122 Table 68: German Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 123 Table 69: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 124 Table 70: German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 125 15c. ITALY 126 Market Analysis 126 Table 71: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 126 Table 72: Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 127 Table 73: Italian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 128 Table 74: Italian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 129 Table 75: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 130 Table 76: Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 131 15d. THE UNITED KINGDOM 132 Market Analysis 132 Table 77: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 132 Table 78: UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 133 Table 79: UK Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 134 Table 80: UK Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 135 Table 81: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 136 Table 82: UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 137 15e. SPAIN 138 Market Analysis 138 Table 83: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 138 Table 84: Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 139 Table 85: Spanish Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 140 Table 86: Spanish Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 141 Table 87: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 142 Table 88: Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 143 15f. RUSSIA 144 Market Analysis 144 Table 89: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 144 Table 90: Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 145 Table 91: Russian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 146 Table 92: Russian Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 147 Table 93: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 148 Table 94: Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 149 15g. REST OF EUROPE 150 Market Analysis 150 Table 95: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 150 Table 96: Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 151 Table 97: Rest of Europe Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 152 Table 98: Rest of Europe Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 153 Table 99: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 154 Table 100: Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 155 16. ASIA-PACIFIC 156 A.Market Analysis 156 China - Healthcare Reforms to Propel DES Market 156 Table 101: Coronary Stent Market in China (2010): Percentage Breakdown of Market Share by Company- Shanghai Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic and Others (includes corresponding Graph/Chart) 156 Coronary Stent Market in a Bubble Zone Now 157 Regional Players and their DES Development Efforts 157 Cost Focus Helps Stent Makers Win the Market Stunt 157 B.Market Analytics 158 Table 102: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 158 Table 103: Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 159 Table 104: Asia-Pacific Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008(includes corresponding Graph/Chart) 160 Table 105: Asia-Pacific Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008(includes corresponding Graph/Chart) 161 Table 106: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 162 Table 107: Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 163 17. REST OF WORLD 164 A.Market Analysis 164 Brazil - Low Penetration of DES 164 South Africa - Leading Players 164 Table 108: Leading Players in South African Coronary Stent Market (2010) - Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott and Others (includes corresponding Graph/Chart) 164 B.Market Analytics 165 Table 109: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart) 165 Table 110: Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment - Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart) 166 Table 111: Rest of World Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart) 167 Table 112: Rest of World Historic Review for Coronary Stents by Product Segment - Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart) 168 Table 113: Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 169 Table 114: Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 170 COMPETITIVE LANDSCAPE Total Companies Profiled: 53 (including Divisions/Subsidiaries - 62) ------------------------------------------ Region/Country Players ------------------------------------------ The United States 34 Canada 1 Japan 3 Europe 15 France 1 Germany 5 The United Kingdom 1 Italy 1 Spain 1 Rest of Europe 6 Asia-Pacific (Excluding Japan) 5 Middle-East 2 Africa 2 ------------------------------------------

Summary:

Coronary artery disease is one of the leading causes of death among men and women in recent times. While one in every 5 deaths in the United States occurs due this disease, over fourteen million Americans currently are estimated to have active symptoms of this precarious condition. In this scenario, coronary stents have emerged as an innovative treatment as they assist in keeping the coronary artery open in patients suffering from the condition of coronary restenosis. During the 2006-2007 period, the market for such stents (classified into Bare Metal Stents and Drug Eluting Stents (DES)), witnessed a period of decline as the DES segment was hard hit by clinical reports that raised concerns relating to late-stent thrombosis. However, with the availability of new clinical evidence in 2008 that proved the safety and efficacy of the stents, the DES segment made a come back and is now driving the coronary stents market to reach new heights. With intentions to make great strides in the market, leading coronary stent producers, of late, have been engaged in taking up new research initiatives. Such efforts have ranged from formulating new material types, developing drug-coating techniques, to advancing stent surface technologies. Efforts have also being channelized towards developing less invasive and bioabsorbable coronary stents, which offer an effective alternative to the available invasive stents. As a result, the market is likely to witness many high-profile innovations over the next few years. Coronary stents, despite finding extensive usage in the treatment of cardiac malfunctions and displaying strong growth in the market for medical equipment, are likely to encounter impediments that may risk growth of the market in the long-term. From widespread skepticism on the grounds of implantation safety of metal and drug content of stents and post stenting complications, to the availability of alternate therapies such as laser angioplasty and lesser invasive bypass surgeries, the market is likely to face challenges from many corners. In a quest to obviate such deficiencies, the cardiac care market, of late, has been avidly developing advanced techniques and simpler drug therapies that fix restenosis without the requirement of stenting. Cost benefits offered by such therapies are their unique selling propositions against pricey coronary stents, thereby curtailing the usage of coronary stents in cardiac procedures. The global coronary stents market is led by the developed markets of United States and Europe, as stated by the Global Industry Analysts research report on Coronary Stents, owing to an overwhelming number of angioplasty procedures, high awareness levels and extraordinary penetration levels in the regions. With coronary artery disease being the leading cause of death in the US, it is no surprise that the region is fuelling the maximum demand in the present scenario. The Asia-Pacific market presently accounts for a minor share of the global market, but is expected to display potential for rapid growth and development, fuelled by fast growing markets of China and India, The coronary stents market in Asia-Pacific is projected to witness fast track growth at a sturdy CAGR of over 10% over the analysis period. By product segment, the market for drug eluting stents accounts for a significant chunk of the global coronary stents market, bearing the torch for strong growth prospects. Global Industry Analysts ©

Companies Mentioned

- Angiotech Pharmaceuticals - Abbott Vascular - Biosensors International - Boston Scientific Corp. - Cordis Corporation - Medtronic Inc. - Medtronic Cardiovascular Inc. - OrbusNeich - Terumo Europe N.V